Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10 results about "Cardiac resynchronization therapy" patented technology

Cardiac resynchronisation therapy (CRT or CRT-P) is the insertion of electrodes in the left and right ventricles of the heart, as well as on occasion the right atrium, to treat heart failure by coordinating the function of the left and right ventricles via a pacemaker, a small device inserted into the interior chest wall.

Implantable Medical Device for Cardiac Resynchronization Therapy Featuring an Automatic Adaptation of a Stimulation Parameter

PendingUS20260199687A1Ventricular contractionBiology
Implantable medical device for stimulating a heart includes a proximal electrode pole, and first and second distal electrode poles. During operation, the device performs: a) detecting an intrinsic atrial contraction of the heart; b) detecting an intrinsic ventricular contraction of the heart; c) determining a first intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and ii) the intrinsic ventricular contraction detected with the first distal electrode pole; and determining a second intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and iii) the intrinsic ventricular contraction detected with the second distal electrode pole; d) setting a stimulated atrioventricular conduction time for stimulating the ventricle of the heart with the first and / or second distal electrode poles, the stimulated atrioventricular conduction time being shorter than the shorter of the first and second intrinsic atrioventricular conduction times.
Owner:BIOTRONIK SE & CO KG

Adaptive cardiac resynchronization therapy

PendingUS20260027370A1Heart defibrillatorsHeart stimulatorsFusion beatRat heart
In some examples, a system can be used for delivering cardiac resynchronization therapy (CRT). The system may include a pacing device configured to be implanted within a patient. The pacing device can include a plurality of electrodes, signal generation circuitry configured to deliver ventricular pacing via the plurality of electrodes, and a sensor configured to produce a signal that indicates mechanical activity of the heart. Processing circuitry can be configured to identify one or more features of a cardiac contraction within the signal, and determine whether the contraction was a fusion beat based on the one or more features.
Owner:MEDTRONIC INC

Modulate pacing rate to increase the percentage of effective ventricular capture during atrial fibrillation

The present disclosure pertains to cardiac pacing methods and systems, and, more particularly, to cardiac resynchronization therapy (CRT). In particular, the present disclosure pertains to determining whether a patient is experiencing atrial fibrillation (AF). If the patient is experiencing AF, the efficacy of CRT is determined. A signal is sensed in response to a ventricular pacing stimulus. Through signal processing, a number of features are parsed from the signal and a determination is made as to whether the ventricular pacing stimulus evoked a response from the ventricle.
Owner:MEDTRONIC INC

Cardiac resynchronization therapy mode switching using mechanical activity

A method includes determining whether electrical activity is indicative of atrial fibrillation, determining whether mechanical activity is indicative of atrial fibrillation, and adjusting a pacing parameter or mode based on whether the electrical activity and the mechanical activity are indicative of atrial fibrillation. The electrical activity may be detected based on a far-field measurement. The method may be performed using a leadless implantable medical device.
Owner:MEDTRONIC INC

Methods of using activin receptor type ii variants

The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.
Owner:KEROS THERAPEUTICS INC

Pacemaker configuration identification system for cardiac resynchronization therapy

A method executed by one or more computing systems involves accessing a cardiogram from a patient, determining an apparent activation location, identifying a pacemaker configuration, creating a visual representation of the patient's heart, marking the apparent activation location on the visual representation, displaying the marked visual representation of the heart, and providing an output indicating the pacemaker configuration.
Owner:THE VEKTOR GRP INC

Heart rate based control of cardiac resynchronization therapy

In some examples, controlling delivery of cardiac resynchronization therapy (CRT) includes storing, in a memory of an implantable medical device system and in association with each of a plurality of heart rates, at least one respective value for an interval between an atrial event and a ventricular event. Processing circuitry of the implantable medical device system may determine a heart rate of a patient and select one of the stored values for the interval between the atrial event and the ventricular event associated with the determined heart rate. The processing circuitry may further determine whether to control therapy delivery circuitry of the implantable medical device system to deliver fusion pacing or biventricular pacing, based on the selected one of the stored values for the interval between the atrial event and the ventricular event.
Owner:MEDTRONIC INC

Devices, systems, and methods for cardiac resynchronization therapy

The present technology generally includes devices, systems, and methods for providing electrical stimulation to the left ventricle of a human heart in a patient suffering from Left Bundle Branch Block (LBBB). In particular, the present technology includes an implantable receiver-stimulator and an implantable controller-transmitter for leadless electrical stimulation of the heart. The receiver-stimulator can include one or more sensors capable of detecting the electrical conduction of the heart and the receiver-stimulator can be configured to pace the stimulation of the left ventricle based off the sensed electrical conduction to achieve synchronization of the left and right ventricles.
Owner:EBR SYSTEMS INC

Implantable medical device for cardiac resynchronization therapy featuring automatic adaptation of stimulation parameters

PendingCN122161646AHeart stimulatorsVentricular contractionAv conduction
The invention relates to an implantable medical device for stimulating a human or animal heart, the device comprising a single electrode (20) comprising a proximal electrode pole (213) designed and arranged to be implanted within an atrium (2) of the heart (1) to be stimulated and a distal electrode pole (203) designed and arranged to be implanted within a septum (13) of the heart (1) to be stimulated. During operation, the implantable medical device performs the following steps: a) detecting (500) an intrinsic atrial contraction of the heart (1) to be stimulated with the proximal electrode pole (213) or stimulating (500) the atrium (2) of the heart (1) to be stimulated with the proximal electrode pole (213); b) detecting (530) an intrinsic ventricular contraction of the heart (1) to be stimulated with the distal electrode pole (203); c) determining (530) an intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and ii) the intrinsic ventricular contraction; d) setting (550) a stimulated atrioventricular conduction time for stimulating a ventricle (3, 5) of the heart (1) to be stimulated with the distal electrode pole (203), the stimulated atrioventricular conduction time being shorter than the intrinsic atrioventricular conduction time.
Owner:BIOTRONIK SE & CO KG